These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32125400)

  • 21. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 22. Omnicare forgot to mention ... Part D's effect not factored in its argument for hostile PharMerica takeover.
    Lee J
    Mod Healthc; 2012 Feb; 42(6):14. PubMed ID: 22356083
    [No Abstract]   [Full Text] [Related]  

  • 23. Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
    Daniel H; Bornstein SS;
    Ann Intern Med; 2019 Dec; 171(11):825-827. PubMed ID: 31711137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. States on the Front Line: Addressing America's Drug Pricing Problem.
    Riley T; Lanford S
    J Leg Med; 2019; 39(2):81-93. PubMed ID: 31503529
    [No Abstract]   [Full Text] [Related]  

  • 25. Examining the impact of Part D on nursing home residents.
    Hudson N
    Find Brief; 2010 May; 13(4):1-3. PubMed ID: 21121179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
    Latham SR
    J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members.
    Trish E; Gascue L; Ribero R; Van Nuys K; Joyce G
    JAMA Intern Med; 2021 Oct; 181(10):1414-1416. PubMed ID: 34228050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 30. Higher Drug Prices from Anticompetitive Conduct: Three Case Studies.
    Carrier MA
    J Leg Med; 2019; 39(2):151-167. PubMed ID: 31503532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
    Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
    Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 33. Presenting Germany's drug pricing rule as a cost-per-QALY rule.
    Gandjour A
    Health Care Manag Sci; 2012 Jun; 15(2):103-7. PubMed ID: 22187356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations for Lowering Prescription Drug Spending in Public Programs.
    Jazowski SA; Dusetzina SB
    Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
    [No Abstract]   [Full Text] [Related]  

  • 35. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 36. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
    Gudiksen KL; King JS
    J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
    [No Abstract]   [Full Text] [Related]  

  • 37. States as Activists.
    Buck ID
    J Leg Med; 2019; 39(2):121-136. PubMed ID: 31503528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
    Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
    BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medicare program; Medicare Advantage and prescription drug benefit programs: negotiated pricing and remaining revisions; prescription drug benefit program: payments to sponsors of retiree prescription drug plans. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2012 Jan; 77(8):1877-83. PubMed ID: 22359793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gift giving.
    Raszkowski RR
    S D J Med; 2002 Dec; 55(12):513-4. PubMed ID: 12516357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.